Overview

Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction

Status:
Completed

Trial end date:
2017-05-01

Target enrollment:
0

Participant gender:
All

Summary

This study evaluates the efficacy of Prasugrel and Ticagrelor in the treatment of acute myocardial infarction.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Faculty Hospital Kralovske Vinohrady

Treatments:

Prasugrel Hydrochloride
Ticagrelor

Criteria

Inclusion Criteria:

1. Acute myocardial infarction (> 1mm ST elevation in at least 2 related leads or ST
depression > 2mm in 3 leads or new BBB) with an indication to emergent (within 120
minut from admission to the PCI center) coronary angiography and PCI,

2. Signed informed consent.

Exclusion Criteria:

1. History of stroke,

2. Serious bleeding within last 6 months,

3. Indication to an oral anticoagulation (e.g. atrial fibrillation, artificial valve,
thromboembolism etc...)

4. Use of ≥ 300 mg of clopidogrel or another antiplatelet agent (except of aspirin and
lower dose of clopidogrel) before randomization,

5. Low body weight (<60 kg) in an older patient (>75 years of age),

6. Moderate or severe liver dysfunction,

7. Ongoing therapy with a strong CYP3A4 inhibitor (e.g. ketoconazole, clarythromycine,
nefazodone, ritonavir, atazanavit),

8. Hypersensitivity to prasugrel or ticagrelor.